{
  "report_rows": [
    {
      "kpi": "Adj. EPS (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$1.11 vs. cons $1.04",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "PDx Revenue (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$825M vs. cons $798M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "PCS Organic Revenue (Q2 2026)",
      "prediction": "MISS",
      "answer": "pred ~-5% organic vs. cons ~-3.6% implied",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY 2026 Adj. EPS (FY 2026)",
      "prediction": "BETTER",
      "answer": "guide ~$4.90-$5.05 vs. cons $4.88",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY 2026 Organic Revenue Growth (FY 2026)",
      "prediction": "UNCHANGED",
      "answer": "guide 3%-4% reaffirmed vs. cons 3.5%",
      "confidence": "HIGH"
    },
    {
      "kpi": "Flyrcado / PDx Commentary (FY 2026)",
      "prediction": "BETTER",
      "answer": "dose acceleration update; reaffirm $500M+ 2028 target",
      "confidence": "HIGH"
    },
    {
      "kpi": "PCS Strategic Review (Ongoing)",
      "prediction": "BETTER",
      "answer": "sharper language on timeline or separation optionality",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 3.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 2.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 positive day-0 persists as H2 estimates revised up; CFO transition caps magnitude",
  "day5_confidence": "MEDIUM"
}